Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cataract: later-stage trial registry
20 of 85 indexed Cataract trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #165 of 28,707 conditions by registered trial count.
85 US clinical trials · 20 currently recruiting · #165 of 28,707 conditions by registered trial count
Cataract: 85 US clinical trials tracked, 20 recruiting.
Cataract is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 30 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Alcon Research, running 12 of these trials.
Enrollment posture brief
Registry condition cataract
OPEN 20 | RECR 24% | LATE 30 | EARLY 5 | RANK #165 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Acute Lymphoblastic Leukemia (ALL) (24% recruiting · 17 trials)
Cataract lists 20 open slots (24% of 85 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cataract on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cataract is recruiting below its size-band peers.
20 of 85 indexed trials (23.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cataract trials is spread across many organizations.
Alcon Research accounts for 12 of 85 trials (14.1%). 52 distinct sponsors appear on at least one study for this condition label.
-
Typical Cataract enrolment sits around 94 participants.
Median target enrolment is 94 among the 84 trials that report a genuine target (sentinel values excluded). 46 of those (54.8%) plan for fewer than 100 participants.
-
Cataract research is mostly interventional.
62 interventional and 23 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
85 total, page 1 of 2
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
Oregon Health and Science University
NCT00532051
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Melt Pharmaceuticals
NCT06383273
IC-8 Apthera IOL New Enrollment Post Approval Study
Bausch & Lomb Incorporated
NCT06060041
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
SpyGlass Pharma
NCT07218783
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
SpyGlass Pharma
NCT07218796
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
Berkeley Eye Center
NCT06922084
Intraoperative OCT Guidance of Intraocular Surgery II
Duke University
NCT03713268
To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.
The New York Eye & Ear Infirmary
NCT07425496
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
Metrolina Eye Associates, P
NCT07222150
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
Inder Paul Singh, M.D.
NCT06681688
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
University of California, San Francisco
NCT05157113
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
EyePoint Pharmaceuticals
NCT05191706
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
Aloha Vision Consultants
NCT07176416
Refractive Outcomes Utilizing Two SS-OCT Biometers for IOL Power Calculations
The Eye institute of Utah
NCT06801678
Evaluation of a Monofocal Intraocular Lens
Carl Zeiss Meditec
NCT06428955
Outcomes of Clareon PanOptix Pro in Patients With Prior Myopic Refractive Surgery
Juliette Eye Institute Research Center
NCT06555289
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
Sharp HealthCare
NCT07301385
Odyssey Evaluation in Post LASIK Patients
Center For Sight
NCT07260695
Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery
Vold Vision P.L.L.C
NCT05624398
Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%
DHS Consulting
NCT06539637
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
Columbia University
NCT04271709
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
Bausch & Lomb Incorporated
NCT06333015
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
SpyGlass Pharma
NCT06120842
Age-Related Eye Disease Study (AREDS) Follow-Up
National Eye Institute (NEI)
NCT00594672
Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement
Alanna Nattis, DO
NCT04570579
Quatera 700 vs. Centurion
Carolina Eyecare Physicians
NCT06225362
Cataract Monitored Anesthesia Care (MAC) Feasibility Pilot Study
University of California, San Francisco
NCT06506669
Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts
National Eye Institute (NEI)
NCT00056771
A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
Johns Hopkins University
NCT00348621
The Effects of Music and Television on Intraoperative Hypertensive Events in Cataract Surgery
Montefiore Medical Center
NCT06356324
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
AcuFocus
NCT03633695
I-ZIP Ocular Bandage Pivotal Study
Ocular Therapeutix
NCT00774228
Clinical Investigation of the Clareon® Intraocular Lens (IOL)
Alcon Research
NCT03170154
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Bausch & Lomb Incorporated
NCT01591161
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
Xigen
NCT02235272
A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)
Melt Pharmaceuticals
NCT05133518
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Bausch & Lomb Incorporated
NCT01230125
Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens
Johnson & Johnson Surgical Vision
NCT03949335
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
Abbott Medical Optics
NCT00747227
Clinical Investigation of AcrySof® IQ PanOptix™ IOL Model TFNT00
Alcon Research
NCT03280108
A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)
Alcon Research
NCT03274986
Clinical Investigation of the Next-Generation Intraocular Lenses
Abbott Medical Optics
NCT03372434
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Salvat
NCT04249076
Clareon Toric vs Eyhance Toric
Alcon Research
NCT05481125
To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
Alcon Research
NCT00763360
The Heidelberg Engineering ANTERION Anterior Segment Cornea and IOL Precision and Agreement Study
Heidelberg Engineering
NCT04130490
Study of T-PRED(TM) Compared to Pred Forte(R) II
Bausch & Lomb Incorporated
NCT00854061
Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)
Alcon Research
NCT00733512
Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.
Hoya Surgical Optics
NCT01292629
Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
Alcon Research
NCT00762021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 10 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Cataract records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cataract trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cataract page
85 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Cataract trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alcon Research sponsors the most Cataract trials on record, review their full trial history before evaluating a specific study. See Alcon Research's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cataract condition card totals 85 registered trials; most-linked intervention Timolol Maleate Ophthalmic Solution, 0.5%; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.